Background: Cardiotoxicity is a known complication of certain breast cancer therapies, but rates come from clinical trials with design features that limit external validity. The ability to accurately identify cardiotoxicity from administrative data would enhance safety information.
C ardiotoxicity is a known complication of certain systemic chemotherapies. 1 Specifically, the development of cardiomyopathy (CM) with associated left ventricular systolic dysfunction and symptomatic heart failure (HF) are well-documented adverse effects of anthracycline-based therapies and trastuzumab adjuvant therapy used to treat breast cancer. [2] [3] [4] However, estimates of risk have been derived from randomized controlled trials (RCTs) with design features that may limit their external validity. Existing RCTs largely excluded older patients and those with comorbidities, especially preexisting cardiovascular conditions that may potentially be associated with higher rates of drug toxicity. For example, of the 3 major trials of trastuzumab published in 2005 and 2006 that led to its widespread use, only 16% of women enrolled were 60 years or older [5] [6] [7] compared with >50% in the overall US invasive breast cancer population and approximately 40% of the HER2-positive population. 8 In addition, all 3 of these trastuzumab trials excluded women with a history of HF, CM, coronary artery disease, uncontrolled hypertension, valvular disease, or unstable arrhythmias. More recent RCTs comparing the safety and efficacy of various chemotherapy regimens in HER-2-positive breast cancer have continued to enroll a majority of patients below 50 years of age and exclude patients with major cardiovascular risk factors. 9 Therefore, extrapolation of trial results to the routine care setting leaves major questions about real-world outcomes. 10 Given the variability of treatment and greater vulnerability of patients with cancer treated in actual clinical practice, assessment of treatments and subsequent outcomes in community settings may improve our understanding of overall safety. The increasing use of health information technology potentially allows for automated identification and characterization of populations of patients with breast cancer, their treatments, and their subsequent outcomes from among large, contemporary, real-world datasets. Although diagnostic codes have been used to identify incident and prevalent HF among general patient cohorts, [11] [12] [13] [14] [15] the accuracy of existing claims-based algorithms to identify HF/CM when applied to patients who also have a concurrent diagnosis of breast cancer is unknown. A variety of potential biases are possible. The major comorbidity of breast cancer has the potential to dominate claims-based coding leading to undercoding of HF/CM. Conversely, concerns about the possibility of chemotherapy-induced cardiotoxicity may result in overcoding of HF/CM. Previously published claimsbased data analyses investigating cardiotoxicity among breast cancer patients have not validated their use of administrative codes, [16] [17] [18] and consequently have drawn criticism. 19 The multicenter Cancer Research Network (CRN) 20 offers an ideal setting for evaluating the performance of administrative diagnostic codes. The CRN is a consortium of 14 nonprofit research centers based in integrated healthcare delivery organizations within the HMO Research Network. 20 Our objective was to test alternative strategies for identifying cardiotoxicity [ie, symptomatic HF, CM, reduction in left ventricular ejection fraction (LVEF)] using electronic claims-based data.
METHODS

Patient Population
We included women diagnosed with incident invasive breast cancer from January 1, 1999 through December 31, 2007, who were enrolled in 1 of 8 CRN health plans: Group Health Cooperative, Harvard Pilgrim Health Care (restricted to women receiving care at Harvard Vanguard Medical Associates, a multispecialty integrated medical practice), Henry Ford Hospital and Health System, Marshfield Clinic, and Kaiser Permanent regions in Colorado, Georgia, Northern California, and Northwest. Women had to be enrolled for at least 12 months before breast cancer diagnosis, with censoring after death or disenrollment through December 31, 2008. Presence of invasive breast cancer was determined from existing tumor registries, as previously described. 20 The majority of data for this study were collected through the CRN Virtual Data Warehouse (VDW), which has been described in detail elsewhere. 20 This study was approved by the Group Health Institutional Review Board for Group Health and 5 other sites that ceded review to GH, and separately by the Institutional Review Boards at Marshfield Clinic and Henry Ford Health System.
To enrich the sample with patients more likely to receive chemotherapy, the eligible population (N = 13,472) was further restricted to a final cohort women who had either tumor size Z2 cm or positive lymph nodes (N = 6460). We then used stratified random sampling to select women for detailed chart abstraction. The stratified random sampling algorithm oversampled for patients (1) from small health systems, (2) with administrative codes for HF/CM, and (3) with exposure to certain chemotherapy (Appendix Table A1 shows sampling protocol). A total of 50 patients from each of the 8 CRN health care systems were chosen to create a chart abstraction cohort (N = 400).
Administrative Codes for HF and CM
Administrative codes chosen as potentially representing cardiotoxicity were all International Classification of Diseases, 9th Edition, Clinical Modification (ICD-9) diagnosis codes representing HF or CM: 398.91, 402.x1, 402.x3, 404.x1, 404.x3, 422.90, 425.4, 425.9, 428.xx. These codes were modeled on an earlier HF claims-based algorithms, 12, 13 with the addition of the 425 "cardiomyopathy" codes due to the nature of cardiotoxicity, although some previously validated versions have included 425 coding. 11 Codes were available as part of the VDW, and those occurring 12 months before to 12 months after breast cancer diagnosis were included in this analysis. Although pharmacy data for common HF drugs and Physicians' Current Procedural Terminology-4codes HF-related imaging studies and procedures were initially considered for inclusion in the algorithm, preliminary analysis showed them to be highly nonspecific (eg, angiotensin converting enzyme inhibitors are primarily prescribed for hypertension) or highly insensitive (eg, implantable cardioverter-defibrillator use was extremely rare). Furthermore, inclusion of LVEF measures into an automated algorithm was not feasible for the vast majority of cardiac imaging studies due to the free text nature of such data storage.
Chemotherapy Exposure
To ascertain detail on the type and timing of chemotherapy received, we used VDW procedure and pharmacy files (also non-VDW chemotherapy databases at some sites) to extract Healthcare Common Procedure Coding System and National Drug Codes specific to anthracyclines and trastuzumab with dates of administration. We also extracted CPT-4 codes related to chemotherapy infusion with dates of administration. All data were extracted up to 12 months after breast cancer diagnosis. Summary variables described whether women had any of the following treatment: anthracyclines, trastuzumab, other chemotherapy, unknown chemotherapy, or none. 21 
Manual Abstraction of the Medical Record
Trained abstractors reviewed the electronic and paper medical record from 12 months before breast cancer diagnosis to 12 months after breast cancer diagnosis. Abstractors received 1 initial 2-hour group training with a lead abstractor, and a subsequent 1-hour training after abstracting 10 records. Abstractors were instructed to review all chart notes within the 24-month window for any discussions of HF/CM (see Appendix Table A2 for a list of key words). Abstractors recorded verbatim all portions of the notes related to HF/CM, the date of visit, location of visit, and location within the chart. Abstractors were also instructed to record all cardiac imaging studies pertaining to LVEF measures within the 24-month window. Abstractors recorded the type of imaging (echocardiography, nuclear medicine, cardiac catheterization/ventriculogram, cardiac magnetic resonance, computerized tomography, or other), the date of each measurement, and the qualitative and quantitative systolic function measurements. Ten percent of charts from each CRN site were rereviewed by the lead project manager for inconsistencies, inaccuracies, and missing data.
A practicing cardiologist board certified in advanced HF (Dr Allen) then reviewed all abstracted information to make a final assessment of the presence or absence of a clinical diagnosis of HF/CM. The Breast Cancer International Research Group definitions for cardiotoxicity, [5] [6] [7] 9 American College of Cardiology/American Heart Association standards for left ventricular dysfunction, 22 and the European Society of Cardiology algorithm for HF diagnosis 23 were used to provide standards for presence or absence of HF/CM. The final gold standard for HF/CM used in this analysis included either of the following: (1) a clinical diagnosis of HF/CM as determined from the medical record by cardiologist review; or (2) a documented quantitative LVEF of < 50% or reduced qualitative LVEF (mildly, moderately, or severely). Patients were given a designation of "definite," "indeterminate," or "not" HF/CM. The "indeterminate" category was grouped with "not" HF/CM for the primary analyses, with secondary analyses considering these patients as HF/CM.
Prevalent Versus Incident Disease
For the claims-based algorithms, patients with any HF/ CM ICD-9 code present in the 12 months before the diagnosis of breast cancer were defined as having prevalent disease; patients with first HF/CM ICD-9 code identified in the 12 months after the diagnosis of breast cancer were classified as having incident HF/CM. Similar definitions were used for abstracted chart data, with the date of first mention of HF/CM or first LVEF <50% compared with the date of diagnosis of breast cancer. The date of breast cancer diagnosis was used instead of the date of exposure to anthracycline or trastuzumab therapy to create homogeneity between those receiving and those not receiving these therapies, as patients who do not receive therapy have no therapy start date from which to anchor posttherapy analyses. Because of possible detection biases after diagnosis of cancer (ie, a diagnosis of cancer with consideration of cardiotoxic therapy may prompt a more thorough evaluation for preexisting cardiac disease), we performed a secondary analysis whereby the cutoff between prevalent and incident disease was modified to date of exposure to anthracycline or trastuzumab therapy or 70 days after breast cancer diagnosis for unexposed patients (70 d was the median time to therapy initiation in exposed patients).
Claims-based Algorithms
Three ICD-9 HF/CM code algorithms were created a priori: (1) Z1 primary hospital discharge diagnoses of HF/ CM, intended to provide a specific but potentially insensitive algorithm; (2) an HF/CM algorithm previously validated in the general population [Z1 primary hospital discharge diagnosis of HF/CM OR Z3 secondary hospital discharge diagnoses of HF/CM OR Z2 outpatient diagnoses of HF/ CM (excluding emergency department) OR Z3 emergency department HF/CM diagnoses OR Z2 secondary hospital discharge +Z1 outpatient diagnosis of HF/CM], intended to provide a balance between specificity and sensitivity 13 ; and (3) any ICD-9 code for HF/CM, intended to provide a sensitive but potentially nonspecific algorithm.
Statistical Analysis
To assess the degree and direction of bias due to misclassification of HF/CM outcome, we estimated diagnostic accuracy measures for the claims-based algorithms. We compared the 3 ICD-9 code algorithms to a clinical gold standard derived from chart abstraction data. Due to our chart sampling scheme, the prevalence of HF/CM in the chart abstraction sample was higher than in the overall cohort. To standardize the results from the chart review sample back to the overall cohort, we calculated the inverse probability of verification given exposure, outcome, and LVEF status as indicated by the VDW. 24 Calculated weights were scaled to the sample size (N = 400) to provide SEs relative to the size of the validation cohort. Weighting was only applicable to women eligible for the chart review, which included 6460 women with positive lymph nodes and/or tumor sizeZ2.0 cm. We calculated weighted sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) with 95% confidence intervals (CIs). Because of the importance of incident HF/CM in relationship to exposure to potentially cardiotoxic chemotherapy, we further assessed the diagnostic accuracy measures of the 3 different ICD-9 code algorithms for incident versus prevalent HF/CM and exposed versus nonexposed patients. All data analyses were performed using SAS (SAS Inc., Cary, NC).
RESULTS
The initial cohort included 13,472 patients with incident, invasive breast cancer. The population eligible for chart review was limited to 6460 women with either positive lymph nodes or tumors Z2 cm in size, from which algorithm performance was determined. Among this final cohort, 36% of patients were above 65 years of age, 54% received anthracyclines and/or trastuzumab, and 28% of patients received no chemotherapy. Compared with the chart review eligible cohort, the 400 patients selected for detailed chart abstraction were older, had more comorbidity, had greater minority representation, had higher stage of breast cancer, and were more likely to receive chemotherapy than the original population ( Table 1 ).
Distribution of ICD-9 Codes for HF/CM Among Women With Breast Cancer
A primary hospital discharge diagnosis of HF/CM was found in 1.5% of the total cohort, and 10.8% of the oversampled chart abstraction cohort ( Table 2 ). Outpatient ICD-9 codes for HF/CM occurred on Z2 occasions in an additional 2.8% of the total cohort, and 18.0% of the oversampled chart abstraction cohort. Other combinations of ICD-9 codes constituting HF/CM in algorithm #2 were rare. Any ICD-9 code was found in 41.5% of the chart sample.
There was a more than 3-fold variation between sites in the frequency of ICD-9 codes for HF/CM among their breast cancer populations (data not shown). Among possible ICD-9 codes for HF/CM assigned to patients, the general code 428.0 "congestive heart failure, unspecified" was the most frequently used at each of the 8 sites. Codes that specified the acuity and type of HF (eg, 428.21 "acute systolic heart failure") were used 10-fold less frequently than the general 428.0 designation. Codes for CM, 425.4 and 425.9, accounted for 2.9% to 9.0% of HF/CM ICD-9 codes at individual sites. Hypertensive heart disease with HF (402 and 404) codes accounted for <1% of HF/CM ICD-9 codes.
Clinical and Imaging-based Diagnosis of HF/CM Manually Abstracted From Charts Description of HF/CM in the Health Record
Any mention of HF/CM (Appendix) was found in 122 of the 400 abstracted patients (30.5%), with a median of 3.5 unique episodes of care describing HF/CM per positively identified patient. On subsequent review by the study cardiologist, 92 were determined to be "definite" HF/CM, 6 "not" HF/CM, and 24 "indeterminate" due to inadequate documentation to apply strict HF/CM criteria (grouped as "not" for the primary analysis).
Cardiac Imaging Studies
Cardiac imaging studies with estimation of LVEF were found among 259 women (64.8%), with 73 patients having only 1 study, 51 patients with 2 studies, 36 having 3 studies, and 99 having 4 to 13 studies. Echocardiographic modalities were most common. Of the 400 sampled patients, 52 (13.0%) were found to have an LVEF recorded quantitatively at < 50% or qualitatively as mildly, moderately, or severely reduced; 14 of 52 women (26.9%) had documentation of reduced LVEF without a clinical diagnosis of HF/CM in the chart.
Performance of 3 ICD-9 Algorithms in the Breast Cancer Population
The sensitivity, specificity, PPV, and NPV are provided for the 3 different ICD-9-based claims-based algorithms in Table 3 . When assessed against the combined gold standard of chart-abstracted clinical diagnosis and/or reduced LVEF, the balanced algorithm (#2) had a sensitivity of 62% (95% CI, 40%-80%), specificity of 99% (range, 97% to 99%), PPV of 69% (range, 45% to 85%), and NPV of 98% (range, 96% to 99%). Compared with the other algorithms, the balanced #2 algorithm maximized sensitivity and PPV with relatively similar specificity and NPV; using only primary hospital discharge diagnosis ICD-9 codes for HF/CM resulted a sensitivity of only 14%, whereas using any ICD-9 HF/CM codes resulted in a PPV of only 45%. In secondary analyses, when we included patients with an "indeterminate" chart-abstracted clinical diagnosis of HF/CM as disease true positive, the performance of algorithm #2 changed mildly: sensitivity 59% (range, 40% to 76%), specificity 99% (range, 97% to 100%), PPV 82% (range, 58% to 94%), and NPV 97% (range, 95% to 99%).
Algorithm Performance by Prevalent Versus Incident and Exposed Versus Unexposed
The sensitivity, specificity, PPV, and NPV for balanced algorithm #2 in relationship to prevalent and incident HF/CM are provided in Table 4 . Mandating timing concordance between the appearances of claims-based and chart-abstracted HF/CM [ie, both having first appearance before the date of breast cancer diagnosis (prevalent), or both having first appearance after the date of breast cancer diagnosis (incident)] had the expected effect of reduced sensitivity and PPV, though CIs were wide due to decreased sample size. Specifically, of the 61 prevalent cases identified from medical record abstraction, 12 were classified as incident cases by the administrative claims algorithm.
On the basis of existing knowledge of the relationship of chemotherapy with cardiotoxicity, the ICD-9 algorithm performance characteristics of greatest research interest involve identification of incident HF/CM among patients exposed to anthracyclines and/or trastuzumab compared with the background rate of incident HF/CM. Algorithm performance for identification of incident HF/CM among exposed patients trended toward a higher PPV (Table 5) ; although due to smaller numbers of patients, the CIs for performance characteristics are wide.
Secondary analysis showed that among the 29 exposed patients identified by the administrative claims algorithm as having incident HF/CM (Table 5) , 5 patients had their ICD-9 code appear between cancer diagnosis and initiation of anthracycline/trastuzumab therapy; among the 27 unexposed patients identified by the algorithm as having incident HF/ CM, 11 patients had their ICD-9 code appear within 70 days after cancer diagnosis. Similarly, among the 32 exposed patients identified by chart review as having incident HF/ CM, 1 patient had diagnostic information appear between cancer diagnosis and initiation of anthracycline/trastuzumab therapy; among the 14 unexposed patients identified by chart abstraction as having incident HF/CM, 9 patients had their diagnostic information appear within 70 days after cancer diagnosis. Because of the even smaller number of incident cases identified under this delayed definition, algorithm performance characteristics for incident disease become unstable (95% CI for PPV, 0%-96.6%).
DISCUSSION
An algorithm of claims-based ICD-9 codes has moderate sensitivity and high specificity for HF/CM among women with incident invasive breast cancer. We found that the performance of an existing claims-based HF algorithm, modified here to include CM (ICD-9 codes 425.4 and 425.9), was lower in this unique population of breast cancer patients [overall PPV 69% (Table 3) , incident-exposed PPV 42% (Table 5) ] as compared with an earlier validation in a general population of adult patients (PPV 97%). [11] [12] [13] These findings suggest a significant degree of misclassification for this automated HF/CM algorithm among women with invasive breast cancer, which reflects HF/CM overcoding (algorithm false positives) versus incomplete clinical documentation of HF/CM in the medical record (true disease missed by gold standard assessment).
Because the primary application of such an algorithm is assumed to be population-based estimates cardiac events associated with these drugs during real-world use, PPVs in the 40% to 70% range give pause to such an approach. If overcoding is more common among patients after treatment with potentially cardiotoxic agents, significant overattribution from these observational associations is likely. However, because increased screening for cardiac disease is also likely to occur immediately after cancer diagnosis before initiation of chemotherapy, documentation of cardiac disease will then justify the avoidance of potentially cardiotoxic agents in such patients. Therefore, detection biases are likely to have complex implications for estimates of cardiotoxicity. Secondary analyses do suggest that new documentation and coding for HF/CM are particularly likely to occur soon after breast cancer diagnoses in patients who ultimately do not go on to receive anthracycline and/or trastuzumab therapy. Unfortunately, because of limited power in subgroup anal-yses it is impossible to provide precise estimates of the effect of these various biases.
Anthracycline and trastuzumab-related cardiotoxicity is generally thought to manifest as CM documented as a decrease in the LVEF. Therefore, the cases of greatest interest among the broader cohort would be HF with new reductions in LVEF after exposure to these chemotherapies. Because of (1) the absence of serial cardiac imaging studies for the majority of patients, (2) the inability to automatically extract quantitative measures of LVEF from cardiac imaging studies within most electronic health records, and (3) the nonspecific coding patterns for cardiac dysfunction (eg, 428.0 "congestive heart failure, unspecified" accounted for the majority of HF/CM codes; codes such as 428.21 "acute systolic heart failure" were rare), we were forced to use an automated HF/CM algorithm that was indifferent to measures of left ventricular systolic function. Electronic databases in their present form and in the setting of current cardiac surveillance patterns are unlikely to allow for automated algorithms that can accurately distinguish between various types of cardiac dysfunction.
Algorithm decisions regarding trade-offs between sensitivity and specificity are often challenging and depend on the clinical setting to which the algorithm is applied. We can imagine situations where high specificity (reducing false positives) would be paramount and other situations where high sensitivity (reducing false negatives) would be the primary goal. Therefore, we investigated 3 different algorithms purposely designed to optimize different performance characteristics. We found that the balanced algorithm performed as expected (Table 3) , providing comparatively good sensitivity and specificity, and therefore we emphasized it in the remainder of the subanalyses. However, future investigations may wish to use a highly sensitive or highly specific algorithm as circumstances dictate.
The variability in ICD-9 code frequencies for HF/CM within the 8 health delivery systems raises questions regarding the consistency of algorithm performance between institutions. There was nearly a 4-fold institutional difference in the frequency of both prevalent and incident HF/CM coding. However, these coding differences may, in part, reflect differences in institutional patient populations. Coding frequencies were concordant with the average age of the population treated by the institution (data not shown). For example, the site with the highest frequency of HF/CM codes treated a patient population of whom 51% were over 65 years of age, compared with the site with the lowest frequency of HF/CM codes, which treated a patient population of whom only 22% were over 65 years of age. Different institutional culture for claims-based coding may provide an alternative explanation for at least part of these HF/CM coding differences. If the large degree of site-based variability in ICD-9 coding is not primarily a reflection of differences in case mix (eg, age), this raises the concern that claims-based algorithms may have to be evaluated and interpreted independently for institutions with obviously different ICD-9 HF/CM coding practices.
Additional Limitations/Considerations
The manual review of all records by trained abstractors with subsequent review of only select-abstracted data by a cardiologist is less rigorous than earlier studies, which have involved physicians for the entire process of chart abstraction. Other studies evaluating methods for identifying patients with HF have used a variety of standard definitions for HF, including Framingham criteria. 25 However, due to a lack of echocardiographic data on all patients and limitations in the naturalistic collection and recording of many of the criteria used for Framingham criteria (eg, decrease in vital capacity by one third from maximum, nocturnal cough, S3 gallop, hepatojugular reflex), we chose to use provider assessments as recorded in the chart combined with what LVEF data were available to determine the presence or absence of HF/CM. In addition, the chart review was not prospectively designed to make a determination of prevalent versus incident HF/CM in relationship to chemotherapy exposure (the distinction between prevalent and incident disease was before or after the date of breast cancer diagnosis, respectively). Finally, the collection of data in routine care lacks the standardization and detail that is inherent to the conduct of a clinical trial. Therefore, the gold standard Incident by LVEF criteria (with first documented LVEF < 50% occurring after date of breast cancer diagnosis) N = 28 exposed, 8 unexposed (weighted N = presented here may have a greater degree of misclassification than seen in some earlier studies, particularly for incident diagnoses. Prevalent disease was based on ascertainment within the 12 months before breast cancer diagnosis; it is conceivable that more prevalent disease would have been identified had we looked further backwards in time. We only reviewed claims and chart data in the 12 months after breast cancer diagnosis. Most adjuvant chemotherapy is given in the first year, and trastuzumab cardiotoxicity is thought to happen relatively acutely. However, it is well known that anthracycline cardiotoxicity can occur years after exposure. We did not assess for cardiotoxicity that developed more than a year after cancer diagnosis, and therefore coding algorithm performance is unknown for late-onset cardiotoxicity. Finally, due to the delayed and nongranular nature of administrative claims data, such an algorithm has limited utility in real-time identification of individual cardiac events.
CONCLUSIONS
The claims-based ICD-9 algorithms tested here had moderate PPVs for HF/CM. Therefore, claims-based algorithms in the setting of routine care, without the addition of some form of medical record review or other data enhancement, are crude tools for accurately estimating cardiotoxicity among women receiving chemotherapy for breast cancer. In the future, health care forces that promote greater standardization of ICD-9 coding and greater use of serial cardiac imaging with storage of LVEF measures in a way that allows for automated extraction from the electronic health record would improve the performance of automated electronic algorithms for characterizing cardiotoxicity of chemotherapy in community-based populations. Table A1 and Table A2 .
APPENDIX
